Shares of India Glycols crashed 79.8% to ₹225 on September 2, but investors shouldn't panic: the plunge is almost entirely mechanical. The company fixed September 1 as the effective date for its court-approved demerger and September 2 as the record date for allotting shares to existing shareholders.

On September 1, India Glycols officially demerged into three separate entities — India Glycols Limited, IGL Spirits Limited, and Ennature Bio Pharma Limited. The ₹225 price now reflects only the retained chemicals business; the "missing" value will eventually surface in the two new tickers once they begin trading.

  • The Price Drop Is Accounting, Not a Crisis. NSE held a special pre-open session on September 2 due to the demerger of the bio-pharma, spirits, and biofuel businesses. Just as SKF India appeared to drop 54% when it demerged in 2024, the stock "in reality fell around 2 percent" once the new entity's value was included. India Glycols' true performance can only be judged once IGL Spirits and Ennature Bio Pharma list and their shares are priced by the market.

  • Shareholders Get New Shares, Not a Haircut. Shareholders receive one IGL Spirits share for every India Glycols share held, plus one Ennature Bio Pharma share for every three shares held — so a holder of 300 shares gets 300 IGL Spirits shares and 100 Ennature shares.

Post-restructuring, promoters will hold 59.63% in each of the three resulting companies.

  • The Spirits Business Is the Real Prize. IGL Spirits targets EBITDA — operating profit before accounting charges — in excess of ₹500 crore for FY27 and aims to become debt-free from FY28 onwards.

The company aspires to deliver an EBITDA in excess of ₹1,000 crore in the next four to five years. With India's branded liquor market booming, a standalone spirits stock could attract a richer valuation from sector-focused investors.

  • The Chemicals Stub Faces Scrutiny. India Glycols Limited will house the chemicals, glycols, bio-glycols, new specialty products, and industrial gases businesses.

Management aspires to deliver EBITDA of approximately ₹400 crore and a business size of approximately ₹2,500 crore in four to five years. At today's ₹225 stub price, the market is handing this business a modest valuation — creating either a bargain or a warning that investors see growth concentrated elsewhere.

The real test comes when IGL Spirits and Ennature list. Only then will the market reveal whether breaking up India Glycols truly created value — or merely rearranged it.